Want to see AU:RHY full AI Analyst Report?
Rhythm Biosciences Ltd. (RHY) Stock Statistics & Valuation Metrics
Total Valuation
Rhythm Biosciences Ltd. has a market cap or net worth of AUD 22.94M. The enterprise value is AUD 28.21M.
- Market Cap
- AUD 22.94M
- Enterprise Value
- AUD 28.21M
Share Statistics
Rhythm Biosciences Ltd. has 364,059,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 364,059,840
- Owned by Insiders
- 0.10%
- Owned by Institutions
- ―
Financial Efficiency
Rhythm Biosciences Ltd.’s return on equity (ROE) is -1.63 and return on invested capital (ROIC) is -150.82%.
- Return on Equity (ROE)
- -1.63
- Return on Assets (ROA)
- -1.24
- Return on Invested Capital (ROIC)
- -150.82%
- Return on Capital Employed (ROCE)
- -2.00
- Revenue Per Employee
- 3,710.391
- Profits Per Employee
- -257.83K
- Employee Count
- 23
- Asset Turnover
- 0.02
- Inventory Turnover
- 275.00
Valuation Ratios
The current PE Ratio of Rhythm Biosciences Ltd. is -3.56. Rhythm Biosciences Ltd.’s PEG ratio is 0.06.
- PE Ratio
- -3.56
- PS Ratio
- 261.24
- PB Ratio
- 5.98
- Price to FCF
- -4.24
- Price to Operating Cash Flow
- -4.15
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Rhythm Biosciences Ltd. had revenue of 85.34K and earned -5.93M in profits. Earnings per share was -0.02.
- Revenue
- 85.34K
- Gross Profit
- -4.40M
- Operating Income
- -7.46M
- Pretax Income
- -7.51M
- Net Income
- -5.93M
- EBITDA
- -7.27M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -5.23M and capital expenditures -25,803, giving a free cash flow of -5.26M billion.
- Operating Cash Flow
- -5.23M
- Free Cash Flow
- -5.26M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Rhythm Biosciences Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.59%
- Earnings Yield
- -27.27%
Stock Price Statistics
- Beta
- 0.95
- 52-Week Price Change
- -35.71%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.13
- Relative Strength Index (RSI)
- 24.49
- Average Volume (3m)
- 216.53K
Important Dates
Rhythm Biosciences Ltd. upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Rhythm Biosciences Ltd. as a current ratio of 3.61, with Debt / Equity ratio of 6.82%
- Current Ratio
- 3.61
- Quick Ratio
- 3.59
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- -99.70
Taxes
In the past 12 months, Rhythm Biosciences Ltd. has paid -1.58M in taxes.
- Income Tax
- -1.58M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Rhythm Biosciences Ltd. EV to EBITDA ratio is -2.64, with an EV/FCF ratio of -3.65.
- EV to Sales
- 224.82
- EV to EBITDA
- -2.64
- EV to Free Cash Flow
- -3.65
- EV to Operating Cash Flow
- -3.67
Balance Sheet
Rhythm Biosciences Ltd. has AUD 3.44M in cash and marketable securities with AUD 247.98K in debt, giving a net cash position of AUD 3.19M billion.
- Cash & Marketable Securities
- AUD 3.44M
- Total Debt
- AUD 247.98K
- Net Cash
- AUD 3.19M
- Net Cash Per Share
- AUD 0.01
- Tangible Book Value Per Share
- AUD 0.01
Margins
Gross margin is -5151.30%, with operating margin of -8739.15%, and net profit margin of -6948.85%.
- Gross Margin
- -5151.30%
- Operating Margin
- -8739.15%
- Pretax Margin
- -8795.48%
- Net Profit Margin
- -6948.85%
- EBITDA Margin
- -8517.35%
- EBIT Margin
- -8739.15%
Analyst Forecast
The average price target for Rhythm Biosciences Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 239.64%
- EPS Growth Forecast
- -37.21%
Scores
- Smart Score
- 1
- AI Score
- 41